Post-Market Activity Shows Gilead (GILD) Down
Trade-Ideas LLC identified
(
) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Gilead as such a stock due to the following factors:
- GILD has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $728.8 million.
- GILD is down 4% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in GILD with the Ticky from Trade-Ideas. See the FREE profile for GILD NOW at Trade-Ideas
More details on GILD:
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The stock currently has a dividend yield of 2.2%. GILD has a PE ratio of 7. Currently there are 10 analysts that rate Gilead a buy, no analysts rate it a sell, and 7 rate it a hold.
The average volume for Gilead has been 9.5 million shares per day over the past 30 days. Gilead has a market cap of $116.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.21 and a short float of 1.8% with 2.59 days to cover. Shares are down 14.5% year-to-date as of the close of trading on Friday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Gilead as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income.
Highlights from the ratings report include:
- GILD's revenue growth trails the industry average of 20.2%. Since the same quarter one year prior, revenues slightly increased by 2.6%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, GILEAD SCIENCES INC's return on equity significantly exceeds that of both the industry average and the S&P 500.
- The gross profit margin for GILEAD SCIENCES INC is currently very high, coming in at 87.93%. Regardless of GILD's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, GILD's net profit margin of 45.75% significantly outperformed against the industry.
- GILEAD SCIENCES INC's earnings per share declined by 8.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, GILEAD SCIENCES INC increased its bottom line by earning $11.92 versus $7.38 in the prior year. This year, the market expects an improvement in earnings ($12.14 versus $11.92).
- You can view the full Gilead Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.